HIV-1 Gag p55 Antigen, Recombinant
50 µg
$295.00
Skip to product information
HIV-1 Gag p55 Antigen, Recombinant
Catalog no.
HI1A-730-4
$295.00
Protein produced in genetically engineered yeast cells. It covers from (equivalent) Met 1 to Gln 502 of the HIV-1 gag protein (SF-2 isolate). The apparent MW is 56,000 Daltons; pI=9.8. It has been purified by ion exchange chromatography, followed by gel filtration.
- Storage: Stable at least one year at –20°C
- Formulation: Solution at 0.5 mg/mL in 50 mM NaPhosphate, 0.4 M NaCl, 6M Urea, pH 7.9.
-
References:
1.Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985).
2.Expression of heterologous gene proteins in yeast. S. Pichuantes, A.T. Nguyen and A. Franzusoff. In Protein Engineering: Principles and Practices. J.E. Clealand & C.S. Craik Editors, pp. 129-161 (1996).
Publications using HI1A-730
The following scientific publications report use of Austral Biologicals HIV-1 p55/Gag antigen:
- Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells. Loucif et al., Autophagy 18(6):1256-1273 (2022).
- Lipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1. Loucif et al., Autophagy 17(11):3408-3423 (2021).
- USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection. Dagenais-Lussier et al., PLoS Pathog 15(10):e1008060 (2019).
- Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations. Jones et al., J Virol 83(17):8722-8732 (2009).
- Virus-specific interleukin-17-producing CD4+ T cells are detectable in early human immunodeficiency virus type 1 infection. Yue et al., J Virol 82(13):6767-6771 (2008).